A pharmacist holds vials of lenacapavir, the new HIV prevention injectable drug, at the Desmond Tutu Health Foundation’s Masiphumelele Research Site, in Cape Town, South Africa, Tuesday, July 23, 2024, which was one of the sites for Gilead’s lenacapavir drug trial.
Discover more from PressNewsAgency
Subscribe to get the latest posts sent to your email.